Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 1:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dextenza Ophthalmic Insert Clear all

Conditions: Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions: Ozurdex, Bevacizumab; Drug
Lead sponsor: Arman Mashayekhi; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Pred Forte; Drug
Lead sponsor: Lejla Vajzovic, MD, FASRS; Other
Eligibility: 3 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dry Eye
Interventions: Cyclosporine, Loteprednol Etabonate, Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert; Drug
Lead sponsor: Thomas Chester, OD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Brecksville, Ohio

Conditions: Dry Eye
Interventions: Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg), ProLong™ collagen plugs; Drug · Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cataract
Interventions: Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 0 Years to 5 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Aurora, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 11 more

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate; Drug
Lead sponsor: Retina Vitreous Associates of Florida; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Cataract
Interventions: Dexamethasone, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: Prism Vision Group; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Vineland, New Jersey

Conditions: Keratoconus, Unstable, Collagen Crosslinking, Postoperative Pain
Interventions: Dextenza, Prednisolone Acetate; Drug
Lead sponsor: Sight Medical Doctors PLLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Babylon, New York

Conditions: Ocular Disease Requiring Surgery
Interventions: DEXTENZA®; Drug
Lead sponsor: Nathan Steinle; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Paso Robles, California • San Luis Obispo, California • Santa Maria, California

Conditions: Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions: Dextenza 0.4Mg Ophthalmic Insert; Drug
Lead sponsor: Kerry Assil, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Vitreo-Retinal Surgery
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone; Drug
Lead sponsor: Patrick R. Oellers, MD; Network
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Liverpool, New York

Conditions: Dry Eye Syndromes
Interventions: Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears; Drug · Other
Lead sponsor: The Eye Centers of Racine and Kenosha; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Refractive Surgery
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: West Fargo, North Dakota

Conditions: Dry Eye
Interventions: Dexamethasone; Drug
Lead sponsor: Research Insight LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Hemet, California • Laguna Hills, California • St Louis, Missouri

Conditions: Cataract
Interventions: Dextenza 0.4mg intracanalicular Insert, Durezol 0.05% Ophthalmic Emulsion; Drug
Lead sponsor: Cathleen McCabe MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bradenton, Florida

Conditions: Healthy
Interventions: Dexamethasone Ophthalmic, Dilator; Drug · Device
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Refractive Surgery
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone; Drug
Lead sponsor: Vance Thompson Vision; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Cataract
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1%; Drug
Lead sponsor: Wyse Eyecare; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Northbrook, Illinois

Conditions: Glaucoma, Cataract
Interventions: Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: The New York Eye Surgery Center; Other
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Patient Preference
Interventions: Dexamethasone, Standard of care surgery; Drug · Other
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 22 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Pharmacokinetics, Aqueous Dexamethasone, Inflammatory Cytokine Response
Interventions: Dexamethasone Ophthalmic implant; Drug
Lead sponsor: Frank A. Bucci, Jr., M.D.; Other
Eligibility: 55 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Dry Eye Syndromes
Interventions: LipiFlow Thermal Pulsation, Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation; Procedure · Drug
Lead sponsor: Eye Surgeons of Indiana; Network
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Cataract
Interventions: Dexamethasone 0.4 MG [Dextenza]; Drug
Lead sponsor: Grene Vision Group; Other
Eligibility: 65 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Wichita, Kansas

Search by objective public record fields.

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia

Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax

Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses

Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammation and Pain- The LINK Study

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

ACCURATE Study for Subjects With Dry Eyes

DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery

The DEPOT Study (Dry Eye Prescription Options for Therapy)

Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery

A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

A Study for Post op Inflammation After Cataract Surgery

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

Pharmacokinetics of Aqueous Dexamethasone

Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease

The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus In-office Post-Op Day 1